sn-38
Small moleculeexperimental
Clinical trial activity
18 trials · 19 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2002 (NCT00046540)
Timeline
Indications
Studied for
- Breast · Phase 2
- Breast Neoplasms · Phase 1
- Carcinoma · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2
- Ependymoma · Phase 1/Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Glioma · Phase 1/Phase 2
- Hamartoma · Phase 2
- Head and Neck Neoplasms · Phase 1
- Lung Neoplasms · Phase 2
- Medulloblastoma · Phase 1/Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Sarcoma · Phase 1
- Small Cell Lung Carcinoma · Phase 2
- Stomach Neoplasms · Phase 1
- Triple Negative Breast Neoplasms · Phase 2
Mechanism of action
- Topoisomerase IINHIBITOR
Topoisomerase I inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- liposomal sn38
- liposomal sn-38
- nk012
- nk012
- sn-38 liposome
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06986811 | Phase 2 | May 6, 2025 | CEBIOTEX, University of Barcelona |
| NCT06538857 | Phase 2 | Aug 9, 2024 | CEBIOTEX, MFAR Clinical Research |
| NCT06337630 | Phase 1 | Jun 15, 2024 | Curie Institute, Merck, ProLynx LLC |
| NCT06162351 | Phase 2 | Jan 15, 2024 | Curie Institute, ProLynx LLC |
| NCT06161519 | Phase 1/Phase 2 (Phase 2) | Jan 3, 2024 | National Cancer Institute (NCI) |
| NCT06143774 | Phase 1 | Oct 31, 2023 | China Medical University, TaiRx, Inc. |
| NCT05465941 | Phase 2 | Jul 22, 2022 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT04640480 | Phase 1 | Oct 21, 2020 | Cha Medical University, SN BioScience |
| NCT04619056 | Phase 1 | Jun 3, 2020 | CEBIOTEX, University of Barcelona |
| NCT04209595 | Phase 1/Phase 2 (Phase 2) | Dec 27, 2019 | National Cancer Institute (NCI) |
| NCT01238939 | Phase 1 | Aug 1, 2010 | Nippon Kayaku Co.,Ltd. |
| NCT01238952 | Phase 1 | Jul 1, 2010 | Nippon Kayaku Co.,Ltd., SCRI Development Innovations |
| NCT00951613 | Phase 2 | Jul 1, 2009 | Nippon Kayaku Co.,Ltd., SCRI Development Innovations |
| NCT00951054 | Phase 2 | Feb 1, 2009 | Nippon Kayaku Co.,Ltd., SCRI Development Innovations |
| NCT00542958 | Phase 1 | Mar 1, 2007 | Nippon Kayaku Co.,Ltd., SCRI Development Innovations |
| NCT00311610 | Phase 2 | Jan 1, 2006 | Cornell University, National Cancer Institute (NCI) |
| NCT00104754 | Phase 2 | Mar 3, 2005 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00046540 | Phase 1 | Oct 1, 2002 | Insys Therapeutics Inc, Ohio State University, University of South Florida, Wayne State University |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (19)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 5 | 4 | 1 | 2005 |
| Nippon Kayaku Co.,Ltd. | For profit | 5 | 5 | 2 | 2007 |
| SCRI Development Innovations | For profit | 4 | 0 | 2 | 2007 |
| CEBIOTEX | For profit | 3 | 3 | 2 | 2020 |
| Curie Institute | Academic/Hospital | 2 | 2 | 2 | 2024 |
| Mayo Clinic | Academic/Hospital | 2 | 1 | 1 | 2005 |
| ProLynx LLC | For profit | 2 | 0 | 2 | 2024 |
| University of Barcelona | Academic/Hospital | 2 | 0 | 2 | 2020 |
| Cha Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Insys Therapeutics Inc | For profit | 1 | 1 | 1 | 2002 |
| Merck | For profit | 1 | 0 | 1 | 2024 |
| MFAR Clinical Research | For profit | 1 | 0 | 1 | 2024 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2002 |
| SN BioScience | For profit | 1 | 1 | 1 | 2020 |
| TaiRx, Inc. | For profit | 1 | 1 | 1 | 2023 |
| University of South Florida | Academic/Hospital | 1 | 0 | 1 | 2002 |
| Wayne State University | Academic/Hospital | 1 | 0 | 1 | 2002 |
19 organizations
Page 1 / 1